A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells

Multiple myeloma (MM) cells home to the bone marrow (BM) and adhere to extracellular matrix (ECM) proteins and to bone marrow stromal cells (BMSCs). The close cross talk between MM cells and cells of the non-tumor compartment within the BM has a key role in supporting tumor growth, survival and development of drug resistance. This biological scenario has led to a growing interest in novel drugs, targeting MM cells and/or interfering with their human BM milieu (HuBMM).1, 2 Based on this, appropriate in vivo models that recapitulate the complex interactions occurring between MM and its HuBMM are required for preclinical evaluation of new anti-MM agents. To date, the in vivo study of MM pathobiology and the validation of therapeutic anti-MM agents has been carried out using a variety of models of murine MM or human MM xenografts in immunocompromised mice.3 These models, however, do not replicate the HuBMM. The development of the SCID (severe combined immunodeficiency)-hu model has been an important advance, as it was the first model to recapitulate a HuBMM in mice.4, 5, 6 However, although the SCID-hu system remains a highly relevant model for preclinical investigation, it does have important limitations: (i) restricted availability of human fetal bone chips; (ii) the allogeneic nature of the fetal BM milieu versus MM cells; and (iii) the significant heterogeneity of implanted human bone chips, collected from different individuals at different gestational age, that may produce experimental variability.

• Publication year

  2011

• Venue

  Leukemia

• Publication date

  2011-01-14

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1038/leu.2010.300PMID 21233838PMCID 3089835
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues.

  2007cited by this paper
• Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.

  2007cited by this paper
• Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma

  2006cited by this paper
• Poly-epsilon-caprolactone/hydroxyapatite composites for bone regeneration: in vitro characterization and human osteoblast response.

  2006cited by this paper
• A clinically relevant SCID-hu in vivo model of human multiple myeloma.

  2004cited by this paper
• Drug therapy: Multiple myeloma

  2004cited by this paper
• Multiple myeloma

  2001cited by this paper
• Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.

  1998cited by this paper
• The development of a model for the homing of multiple myeloma cells to human bone marrow.

  1997cited by this paper
• Multiple myeloma.

  1948cited by this paper

• Models of myeloma bone disease: In vivo and in vitro approaches.

  2026cites this paper
• Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice

  2024cites this paper
• Establishment of A Three-Dimensional Culture Condition for The U266 Cell Line Based on Peripheral Blood Plasma-Derived Fibrin Gels

  2023cites this paper
• Novel microgel culture system as semi-solid three-dimensional in vitro model for the study of multiple myeloma proliferation and drug resistance.

  2022cites this paper
• In vivo models used in studies of bone metastases

  2022cites this paper
• 3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance

  2021cites this paper
• Tools in Pharmacogenomics Biomarker Identification for Cancer Patients.

  2021cites this paper
• 3D Models of Surrogate Multiple Myeloma Bone Marrow Microenvironments: Insights on Disease Pathophysiology and Patient-Specific Response to Drugs

  2021cites this paper
• Management of Myeloma Bone Lesions

  2021cites this paper
• Rebuilding the hematopoietic stem cell niche: recent developments and future prospects.

  2021cites this paper
• Animal Models of Multiple Myeloma Bone Disease

  2021cites this paper
• Laboratory Mice – A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma

  2021cites this paper
• JunB is a key regulator of multiple myeloma bone marrow angiogenesis

  2021influential citation
• Current Understanding of Myelomatous Mesenchymal Stromal Cells Extended through Advances in Experimental Methods

  2020cites this paper
• Droplet Microfluidics for the ex Vivo Expansion of Human Primary Multiple Myeloma Cells

  2020cites this paper
• Advances in Tissue Engineering and Regeneration

  2020cites this paper
• Multiple myeloma: the (r)evolution of current therapy and a glance into future.

  2020cites this paper
• Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models

  2020cites this paper
• Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma

  2020cites this paper
• Engineering a Humanised Niche to Support Human Haematopoiesis in Mice: Novel Opportunities in Modelling Cancer

  2020cites this paper
• Multiple myeloma: the (r)evolution of current therapy and a glance into future.

  2020cites this paper
• Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of CrbnI391V.

  2020cites this paper
• Animal Models of Multiple Myeloma.

  2019cites this paper
• The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma

  2019cites this paper
• Myeloma Mouse Models in Studying Myeloma-Associated Bone Disease

  2019cites this paper
• Design of spherically structured 3D in vitro tumor models -Advances and prospects.

  2018cites this paper
• Turning Stem Cells Bad: Generation of Clinically Relevant Models of Human Acute Myeloid Leukemia through Gene Delivery- or Genome Editing-Based Approaches

  2018cites this paper
• Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model

  2018cites this paper
• Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation.

  2018cites this paper
• Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment

  2018cites this paper
• Ultraporous, Compressible, Wettable Polylactide/Polycaprolactone Sponges for Tissue Engineering.

  2018cites this paper
• Mouse models of multiple myeloma: technologic platforms and perspectives

  2018cites this paper
• Enhancing proteasome‐inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma

  2018cites this paper
• Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment.

  2017cites this paper
• MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells

  2017cites this paper
• Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma

  2017cites this paper
• The mechanism study of miR‐125b in occurrence and progression of multiple myeloma

  2017cites this paper
• Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma

  2017cites this paper
• Oncogenic role of microRNA-20a in human multiple myeloma

  2017cites this paper
• Preclinical animal models of multiple myeloma.

  2016cites this paper
• Experimental treatment of multiple myeloma in the era of precision medicine

  2016cites this paper
• 3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma?

  2016cites this paper
• Microenvironment-dependent growth of pre-neoplastic and malignant plasma cells in humanized mice

  2016cites this paper
• Mir-221/222 are promising targets for innovative anticancer therapy

  2016cites this paper
• MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment

  2016cites this paper
• Challenges in Multiple Myeloma Chemoprevention: Potential Role of Natural, Synthetic and Endogenous Molecules

  2016cites this paper
• CD4+ T cell-induced macrophage cytotoxicity against tumor cells

  2016cites this paper
• A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications

  2016cites this paper
• Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment.

  2016cites this paper
• Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma

  2016cites this paper
• The Cyclophilin A-CD147 complex promotes bone marrow colonization of B-cell malignancies: implications for therapy

  2015cites this paper
• Ex vivo engineered immune organoids for controlled germinal center reactions.

  2015cites this paper
• A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells

  2015cites this paper
• Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche

  2015cites this paper
• miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies

  2015cites this paper
• Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma

  2015cites this paper
• Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo

  2015cites this paper
• MicroRNAs in multiple myeloma and related bone disease.

  2015cites this paper
• MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.

  2015cites this paper
• 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.

  2015cites this paper
• Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts

  2015cites this paper
• A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.

  2015cites this paper
• Multiple myeloma-related bone disease: state-of-art and next future treatments

  2015cites this paper
• Chapter 43 – In vivo models used in studies of bone metastases

  2015cites this paper
• New Approaches to Predict Outcome and Personalize Therapy in Multiple Myeloma: from microRNAs to Integrated Genomics

  2015cites this paper
• Patient-Specific 3D Microfluidic Tissue Model for Multiple Myeloma

  2014cites this paper
• A p53‐Dependent Tumor Suppressor Network Is Induced by Selective miR‐125a‐5p Inhibition in Multiple Myeloma Cells

  2014cites this paper
• Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities

  2014cites this paper
• Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities

  2014cites this paper
• MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches.

  2014cites this paper
• Mir-34: A New Weapon Against Cancer?

  2014cites this paper
• Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity

  2014cites this paper
• In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma

  2014cites this paper
• Examining a new class of dual CDC7/CDK9 inhibitors, mechanisms of proliferation, and proliferation-based stratification in myeloma

  2014cites this paper
• Immunological Dysregulation in Multiple Myeloma Microenvironment

  2014cites this paper
• Plasmonics and Super-Hydrophobicity: A New Class of Nano-Bio-Devices

  2013cites this paper
• Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma

  2013cites this paper
• Intratibial Injection of Human Multiple Myeloma Cells in NOD/SCID IL-2Rγ(Null) Mice Mimics Human Myeloma and Serves as a Valuable Tool for the Development of Anticancer Strategies

  2013cites this paper
• In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma

  2013cites this paper
• Innovative Models to Assess Multiple Myeloma Biology and the Impact of Drugs

  2013influential citation
• miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease

  2013cites this paper
• New insights, recent advances, and current challenges in the biological treatment of multiple myeloma

  2013cites this paper
• The Role of APRIL in Promoting Cell Cycle Progression and Drug Resistance in Multiple Myeloma

  2013cites this paper
• Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth

  2013cites this paper
• Preclinical models of multiple myeloma: a critical appraisal

  2013cites this paper
• miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells

  2013cites this paper
• Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138‐downregulation and inhibition of migration through actin depolymerization

  2013cites this paper
• Novel In Vivo Models in Myeloma

  2013cites this paper
• Cancer stem cells in acute myeloid leukemia

  2013cites this paper
• The biology of human hematopoietic stem and progenitor cells in acute myeloid leukemia, aging and autologous transplantation

  2013cites this paper
• Emerging pathways as individualized therapeutic target of multiple myeloma

  2013cites this paper
• Immunologic microenvironment and personalized treatment in multiple myeloma

  2013cites this paper
• Ex-Vivo Dynamic 3-D Culture of Human Tissues in the RCCS™ Bioreactor Allows the Study of Multiple Myeloma Biology and Response to Therapy

  2013cites this paper
• Characterization of a Novel Mouse Model of Multiple Myeloma and Its Use in Preclinical Therapeutic Assessment

  2013cites this paper
• Cancer stem cells in acute myeloid leukemia

  2013cites this paper
• From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.

  2013cites this paper
• Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma.

  2012cites this paper
• Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma

  2012cites this paper
• Molecular targets for the treatment of multiple myeloma.

  2012cites this paper
• A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic Disease

  2012cites this paper